Authors
Gitelson D.G.1, Faybushevich A.G.2, Gitelzon E.A.2, Maximkin D.A.2, Chernyaev M.V.2, Veretnik G.I.2, Baranovich V.Yu.2, Mitina N.A.2, Vasiliev A.E.1, Danishian K.I.1
1 National Research Center for Hematology, Moscow
2 RUDN University, Moscow
Abstract
Introduction. Venous stenting is increasingly used in the treatment of venous stenosis and occlusion, but there is currently no consensus on the optimal antithrombotic therapy.
Aim. The aim of this study was to determine the most commonly used antithrombotic treatment regimens and to improve the results of venous stenting in the Russian Federation.
Methods. An electronic survey containing three clinical scenarios of venous stenting: non-thrombotic lesions, post-thrombotic syndrome and acute deep vein thrombosis (DVT) was distributed among experts in the field of venous stenting in Russia. The survey was sent to 43 experts to determine the consensus on the optimal antithrombotic therapy regimen for the above scenarios. Consensus was defined as approval or rejection of the application by ≥ 67% of respondents.
Results. The survey was completed by 32 experts who practice in 19 medical centers in Russia. Three statements met the consensus criteria. Anticoagulant therapy was the preferred treatment during the first 6-12 months after venous stenting for compression venous lesions, as well as for single acute DVT. Lifelong anticoagulant therapy was recommended after recurrent DVT. There was no agreement on the role of long-term antiplatelet therapy.
Conclusion. There is a consensus among experts regarding anticoagulant therapy after venous stenting. However, there is currently no consensus on the role of antiplatelet therapy.
Keywords: venous stenting, antithrombotic therapy, anticoagulants, antiplatelets.
References
1. Raju S, Darcey R, Neglen P. Unexpected major role for venous stenting in deep reflux disease. J Vasc Surg. 2010; 51: 401-408. doi: 10.1016/j.jvs.2009.08.032.
2. Lim CS, Shalhoub J, Davies AH. Deep venous procedures performed in the National Health Service in England between 2005 and 2015. Eur J Vasc Endovasc Surg. 2017; 54: 487-494. doi: 10.1016/j.ejvs.2017.06.019.
3. Raju S, Owen S, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. J Vasc Surg. 2002; 35: 8-14. doi: 10.1067/mva.2002.121054.
4. Neglen P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. J Vasc Surg. 2007; 46: 979-991. doi: 10.1016/j.jvs.2007.06.046.
5. Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation. 2014; 130: 1636-1661. doi: 10.1161/CIR.0000000000000130.
6. Wittens C, Davies AH, Bakgaard N, Broholm R, Cavezzi A, Chastanet S, et al. Management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015; 49: 678-737. doi: 10.1016/j.ejvs.2015.02.007.
7. Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review. Rev Vasc Med. 2014; 2: 88-97.
8. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Phlebology. 2015; 9(4): 1-52. (In Russ).
9. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2): e419S-e496S. doi: 10.1378/chest.11-2301.
10. National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE Guideline. 2015: 12-15.
11. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manage Sci. 1963; 9(3): 458-467. doi: 10.1287/mnsc.9.3.458.
12. Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol. 2003; 56: 1150-1156. doi: 10.1016/s0895-4356(03)00211-7.
13. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001: 195-200. doi: 10.1016/s0020-7489(00)00044-4.
14. Neglen P, Raju S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. J Vasc Surg. 2004; 39: 181-188. doi: 10.1016/s0741-5214(03)01028-0.
15. Langwieser N, Bernlochner I, Wustrow I, Dirschinger RJ, Jaitner J, Dommasch M, et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction. Phlebology. 2016; 31: 430-437. doi: 10.1177/0268355515596289.
16. Kolbel T, Lindh M, Holst J, Uher P, Eriksson KF, Sonesson B, et al. Extensive acute deep vein thrombosis of the iliocaval segment: midterm results of thrombolysis and stent placement. J Vasc Interv Radiol. 2007; 18: 243-250. doi: 10.1016/j.jvir.2006.12.002.
17. Oguzkurt L, Tercan F, Ozkan U, Gulcan O. Iliac vein compression syndrome: Outcome of endovascular treatment with long-term follow-up. Eur J Radiol. 2008; 68: 487-492. doi: 10.1016/j.ejrad.2007.08.019.
18. Jain A, Cifu AS. Antithrombotic therapy for venous thromboembolic disease. JAMA. 2017; 317(19): 2008-2009. doi: 10.1001/jama.2017.1928.
19. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease – antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e669S-e690S. doi: 10.1378/chest.11-2307.
20. McBane RD, Leadley RJ, Baxi SM, Karnicki K, Wysokinski W. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct factor xa inhibitor, compared with antiplatelet agents in pigs. Arterioscler Thromb Vasc Biol. 2008; 28: 413-418. doi: 10.1161/ATVBAHA.107.158691.
21. Geerts WH, Pineo GF, Heit JA, Bergquist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3): 338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
22. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014; 67(4): 401-409. doi: 10.1016/j.jclinepi.2013.12.002.
